Literature DB >> 9875214

Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery.

Y Sadamoto1, K Igase, M Sakanaka, K Sato, H Otsuka, S Sakaki, S Masuda, R Sasaki.   

Abstract

Erythropoietin (EPO) prevents the ischemia-induced delayed neuronal death in the hippocampal CA1 field in gerbils. EPO receptor (EPOR) is also expressed in the cerebral cortex but its function is not known. To examine whether EPO has a neuroprotective action in the cortex, EPO was infused into the cerebroventricles of stroke-prone spontaneously hypertensive rats with permanent occlusion of the left middle cerebral artery. Morris water maze test indicated that EPO infusion alleviated the ischemia-induced place navigation disability. The left (ischemic)-to-right (contralateral nonischemic) (L/R) ratio of cerebrocortical area in the EPO-infused ischemic group was larger than that in the vehicle-infused ischemic group. The occlusion caused secondary thalamic degeneration but infusion of EPO prevented the decrease in the L/R ratio of thalamic area and supported neuron survival in the ventroposterior thalamic nucleus. In situ hybridization indicated that EPOR mRNA was upregulated in the periphery (ischemic penumbra) of a cerebrocortical infarct after occlusion of the middle cerebral artery, suggesting that an increased number of EPOR in neurons facilitates the EPO signal transmission, thereby preventing the damaged area from enlarging.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875214     DOI: 10.1006/bbrc.1998.9748

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  61 in total

1.  Erythropoietin: still on the neuroprotection road.

Authors:  Nelvys Subirós; Diana García Del Barco; Rosa M Coro-Antich
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

2.  Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis.

Authors:  Claudia Bartels; Kira Späte; Henning Krampe; Hannelore Ehrenreich
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

3.  Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.

Authors:  Kosuke Kajitani; Michael Thorne; Michel Samson; George S Robertson
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 4.  Hypoxic preconditioning protects against ischemic brain injury.

Authors:  Frank R Sharp; Ruiqiong Ran; Aigang Lu; Yang Tang; Kenneth I Strauss; Todd Glass; Tim Ardizzone; Myriam Bernaudin
Journal:  NeuroRx       Date:  2004-01

Review 5.  Biological mechanisms of physical activity in preventing cognitive decline.

Authors:  I Lista; G Sorrentino
Journal:  Cell Mol Neurobiol       Date:  2009-12-30       Impact factor: 5.046

6.  Intranasal Erythropoietin Protects CA1 Hippocampal Cells, Modulated by Specific Time Pattern Molecular Changes After Ischemic Damage in Rats.

Authors:  R J Macias-Velez; L Fukushima-Díaz de León; C Beas-Zárate; M C Rivera-Cervantes
Journal:  J Mol Neurosci       Date:  2019-05-03       Impact factor: 3.444

7.  Time-dependent effect of combination therapy with erythropoietin and granulocyte colony-stimulating factor in a mouse model of hypoxic-ischemic brain injury.

Authors:  Ji Hea Yu; Jung Hwa Seo; Jong Eun Lee; Ji Hoe Heo; Sung-Rae Cho
Journal:  Neurosci Bull       Date:  2014-01-16       Impact factor: 5.203

Review 8.  Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration.

Authors:  Suzan Dziennis; Nabil J Alkayed
Journal:  Rev Neurosci       Date:  2008       Impact factor: 4.353

9.  Intranasal injection of recombinant human erythropoietin improves cognitive and visual impairments in chronic cerebral ischemia rats.

Authors:  Yanhui Zhou; Bin Sun; Junhong Guo; Guohong Zhou
Journal:  Biomed Rep       Date:  2020-08-25

10.  Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation.

Authors:  N R Mudalagiri; M M Mocanu; C Di Salvo; S Kolvekar; M Hayward; J Yap; B Keogh; D M Yellon
Journal:  Br J Pharmacol       Date:  2007-10-22       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.